COMPANY
Crinetics Pharmaceuticals, Inc.
FDA-approved therapeutic company Clinical Phase 3
Since the raise (Jan 6, 2026): 4 of 4 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Field Reimbursement Liaison - Southwest | 2 locations (listed on the posting) | Oct 7, 2026 | Oct 8, 2026 |
| Field Reimbursement Liaison - Northwest | 8 locations (listed on the posting) | Sep 23, 2026 | Oct 8, 2026 |
| Medical Director, Clinical Research, Endocrinology | Remote | Sep 23, 2026 | Oct 8, 2026 |
| Senior Clinical Scientist | Remote | Sep 23, 2026 | Oct 8, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (4 open jobs at last check). source ↗
- Trial start Phase 1: Drug-Drug Interaction Study of Atumelnant in Healthy Participants source ↗
- Trial start Phase 2/Phase 3: A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) source ↗
- Raise Follow-on offering: $350M (total, as published), announced Jan 6, 2026. Source: SEC filing. source ↗
- Trial start Phase 3: A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia source ↗
- Trial start Phase 1/Phase 2: A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors source ↗
- Trial start Phase 3: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen source ↗
- Trial start Phase 1: A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants source ↗
- FDA FDA New drug/biologic (novel): PALSONIFY (paltusotine hydrochloride) — NDA219070, Sep 25, 2025. Applicant at approval: Crinetics Pharmaceuticals, Inc. source ↗
- Trial start Phase 2: An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia source ↗
- Trial start Phase 1/Phase 2: A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome source ↗
- Trial start Phase 2: Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) source ↗
- Trial start Phase 2: Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome source ↗
- Trial start Phase 3: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) source ↗
- Trial start Phase 3: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly source ↗
- Trial start Phase 1: Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers source ↗
- Trial start Phase 2: A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) source ↗
- Trial start Phase 1: Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers source ↗
- Trial start Phase 1: A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers source ↗
- Trial start Phase 2: An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) source ↗
- Trial start Phase 2: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) source ↗
- Trial start Phase 1: Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers source ↗
Upcoming milestones
- 2026-10 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome · NCT05804669
- 2027-05 (ESTIMATED) · Phase 3 · A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia · NCT07144163
- 2027-08 (ESTIMATED) · Phase 3 · Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen · NCT07087054
- 2027-08 (ESTIMATED) · Phase 1/Phase 2 · A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors · NCT07129252
- 2029-07 (ESTIMATED) · Phase 2 · An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia · NCT06712823
- 2030-03 (ESTIMATED) · Phase 2/Phase 3 · A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) · NCT07159841
Open jobs 4
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Field Reimbursement Liaison - Southwest | 2 locations (listed on the posting) | Oct 7, 2026 | Oct 8, 2026 | Senior |
| Field Reimbursement Liaison - Northwest | 8 locations (listed on the posting) | Sep 23, 2026 | Oct 8, 2026 | Senior |
| Medical Director, Clinical Research, Endocrinology | Remote | Sep 23, 2026 | Oct 8, 2026 | Senior |
| Senior Clinical Scientist | Remote | Sep 23, 2026 | Oct 8, 2026 | Senior |
Funding
- Follow-on offering: $350M (total, as published), announced Jan 6, 2026. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 19
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07159841 | A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) | Phase 2/Phase 3 | Recruiting | Jan 22, 2026 | 2030-03 (estimated) |
| NCT07144163 | A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia | Phase 3 | Recruiting | Dec 11, 2025 | 2027-05 (estimated) |
| NCT07087054 | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Phase 3 | Recruiting | Nov 19, 2025 | 2027-08 (estimated) |
| NCT05907291 | Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) | Phase 2 | Completed | Jul 3, 2023 | Aug 22, 2025 (actual) |
| NCT05804669 | A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome | Phase 1/Phase 2 | Active, not recruiting | Oct 12, 2023 | 2026-10 (estimated) |
| NCT07570082 | Drug-Drug Interaction Study of Atumelnant in Healthy Participants | Phase 1 | Completed | May 28, 2026 | Jun 30, 2026 (actual) |
| NCT07129252 | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | Phase 1/Phase 2 | Recruiting | Nov 26, 2025 | 2027-08 (estimated) |
| NCT04261712 | A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) | Phase 2 | Terminated | Jan 29, 2020 | Jun 30, 2026 (actual) |
| NCT05192382 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) | Phase 3 | Terminated | Dec 17, 2021 | Jan 20, 2024 (actual) |
| NCT04837040 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly | Phase 3 | Terminated | May 12, 2021 | Jul 10, 2023 (actual) |
| NCT06712823 | An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia | Phase 2 | Recruiting | Feb 25, 2025 | 2029-07 (estimated) |
| NCT05361668 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | Phase 2 | Completed | Apr 22, 2022 | Mar 7, 2024 (actual) |
| NCT07221084 | A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants | Phase 1 | Completed | Oct 28, 2025 | Feb 7, 2026 (actual) |
| NCT03792555 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) | Phase 2 | Completed | Mar 11, 2019 | Jul 15, 2020 (actual) |
| NCT03789656 | An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) | Phase 2 | Completed | Mar 12, 2019 | Aug 3, 2020 (actual) |
| NCT06048887 | Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers | Phase 1 | Completed | Dec 18, 2020 | Apr 11, 2022 (actual) |
| NCT03936166 | A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers | Phase 1 | Completed | Apr 29, 2019 | Dec 16, 2019 (actual) |
| NCT04246749 | Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers | Phase 1 | Completed | Sep 17, 2019 | Oct 25, 2019 (actual) |
| NCT03276858 | Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers | Phase 1 | Completed | Sep 22, 2017 | Apr 30, 2018 (actual) |
FDA records (last 2 years)
- FDA New drug/biologic (novel): PALSONIFY (paltusotine hydrochloride) — NDA219070, Sep 25, 2025. Applicant at approval: Crinetics Pharmaceuticals, Inc. source ↗
NIH awards 15
- NIH award 5R44DK115290-03 FY2019: $896,817 awarded for that fiscal year; activity R44 (SBIR); PI BETZ, STEPHEN F; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Nonpeptide, oral somatostatin ag source ↗
- NIH award 4R44DK115290-02 FY2018: $998,741 awarded for that fiscal year; activity R44 (SBIR); PI BETZ, STEPHEN F; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Nonpeptide, oral somatostatin ag source ↗
- NIH award 5R44DK088501-05 FY2018: $1,354,308 awarded for that fiscal year; activity R44 (SBIR); PI STRUTHERS, RICHARD SCOTT; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Biased Agonism In GPC source ↗
- NIH award 1R43DK115245-01 FY2017: $299,510 awarded for that fiscal year; activity R43 (SBIR); PI STRUTHERS, RICHARD SCOTT; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Discovery of novel smal source ↗
- NIH award 1R44DK115290-01 FY2017: $297,358 awarded for that fiscal year; activity R44 (SBIR); PI BETZ, STEPHEN F; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Nonpeptide, oral somatostatin ag source ↗
- NIH award 2R44DK088501-04A1 FY2017: $1,448,103 awarded for that fiscal year; activity R44 (SBIR); PI STRUTHERS, RICHARD SCOTT; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Biased Agonism In G source ↗
- NIH award 5R44HD070568-03 FY2016: $716,200 awarded for that fiscal year; activity R44 (SBIR); PI BETZ, STEPHEN F; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Nonpeptide Kisspeptin Antagonist source ↗
- NIH award 1R44NS092231-01 FY2015: $326,121 awarded for that fiscal year; activity R44 (SBIR); PI STRUTHERS, RICHARD SCOTT; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Small molecule somatost source ↗
- NIH award 2R44HD070568-02 FY2015: $783,766 awarded for that fiscal year; activity R44 (SBIR); PI BETZ, STEPHEN F; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Nonpeptide Kisspeptin Antagonist source ↗
- NIH award 5R44DK088501-03 FY2014: $1,162,633 awarded for that fiscal year; activity R44 (SBIR); PI STRUTHERS, RICHARD SCOTT; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Biased Agonism In GPC source ↗
- NIH award 1R43EY024185-01 FY2014: $224,092 awarded for that fiscal year; activity R43 (SBIR); PI BETZ, STEPHEN F; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Peripheral administration of non source ↗
- NIH award 2R44DK088501-02A1 FY2013: $999,917 awarded for that fiscal year; activity R44 (SBIR); PI STRUTHERS, RICHARD SCOTT; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Biased Agonism In GPC source ↗
- NIH award 1R43HD070568-01A1 FY2012: $296,283 awarded for that fiscal year; activity R43 (SBIR); PI BETZ, STEPHEN F; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Nonpeptide Kisspeptin Antagoni source ↗
- NIH award 1R43DK088501-01A1 FY2011: $282,070 awarded for that fiscal year; activity R43 (SBIR); PI STRUTHERS, RICHARD SCOTT; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Biased Agonism In GPC source ↗
- NIH award 1R43GM088912-01A1 FY2010: $237,895 awarded for that fiscal year; activity R43 (SBIR); PI STRUTHERS, RICHARD SCOTT; recipient as written: CRINETICS PHARMACEUTICALS, INC., SAN DIEGO, CA. Biosensors of GPCR Ac source ↗
Raises and investors new
- InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗
Connect
See your connections at Crinetics Pharmaceuticals on LinkedIn (search by name, results not checked)